The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico

Piepoli, 2016, Eur. Heart J., 37, 2315, 10.1093/eurheartj/ehw106 Mancia, 2006, Total cardiovascular risk: a new treatment concept, J. Hypertens. Suppl., 24, S17, 10.1097/01.hjh.0000220099.12154.c1 Chowdhury, 2013, Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences, Eur. Heart J., 34, 2940, 10.1093/eurheartj/eht295 Ibanez, 2018, Eur. Heart J., 39, 119, 10.1093/eurheartj/ehx393 Williams, 2018, J. Hypertens., 36, 1953, 10.1097/HJH.0000000000001940 Webster, 2017, Putting polypills into practice: challenges and lessons learned, Lancet, 389, 1066, 10.1016/S0140-6736(17)30558-5 Bahiru, 2017, Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases, Cochrane Database Syst. Rev., CD009868 Webster, 2016, Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries, Int. J. Cardiol., 205, 147, 10.1016/j.ijcard.2015.12.015 Castellano, 2015, Polypill, el policomprimido cardiovascular: del concepto a la realidad en España, Rev. Espanola de Cardiol. Supl., 15, 19 Castellano, 2019, Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study, Arch. Med. Res., 50, 31, 10.1016/j.arcmed.2019.04.001 Chapman, 2011, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, Eur. Heart J., 32, 1345, 10.1093/eurheartj/ehr112 Grundy, 1997, Small LDL, atherogenic dyslipidemia, and the metabolic syndrome, Circulation, 95, 1, 10.1161/01.CIR.95.1.1 Jacobson, 2004, Characteristics of US adults with the metabolic syndrome and therapeutic implications, Diabetes Obes. Metab., 6, 353, 10.1111/j.1462-8902.2004.00354.x Ponte-Negretti, 2017, Int. J. Cardiol., 243, 516, 10.1016/j.ijcard.2017.05.059 Aguilar-Salinas, 2001, High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey, J. Lipid Res., 42, 1298, 10.1016/S0022-2275(20)31581-9 Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin. Chem., 18, 499, 10.1093/clinchem/18.6.499 McNamara, 1998, Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study, Clin. Chem., 44, 1224, 10.1093/clinchem/44.6.1224 Castelli, 1983, Summary estimates of cholesterol used to predict coronary heart disease, Circulation, 67, 730, 10.1161/01.CIR.67.4.730 Brehm, 2004, Relationship between serum lipoprotein ratios and insulin resistance in obesity, Clin. Chem., 50, 2316, 10.1373/clinchem.2004.037556 Ray, 2012, A simple way to identify insulin resistance in non-diabetic acute coronary syndrome patients with impaired fasting glucose, Indian J. Endocrinol. Metab., 16, S460 Dobiasova, 2011, Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography, J. Lipid Res., 52, 566, 10.1194/jlr.P011668 Catapano, 2016, 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias, Eur. Heart J., 37, 2999, 10.1093/eurheartj/ehw272 The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 290 (2019) 140-205. https://doi.org/10.1016/j.atherosclerosis.2019.08.014. Mendez-Garcia, 2019, Six Month Polypill Therapy Improves Lipid Profile in Patients with Previous Acute Myocardial Infarction: The Heart-Mex Study, Arch. Med. Res., 50, 197, 10.1016/j.arcmed.2019.08.002 Khatib, 2016, Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data, Lancet, 387, 61, 10.1016/S0140-6736(15)00469-9 González-Juanatey, 2020, Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?, Revista Española de Cardiología (English Edition) Selak, 2016, Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease, Eur. J. Prev. Cardiol., 23, 1393, 10.1177/2047487316638216 Hokanson, 1996, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies, J. Cardiovasc. Risk, 3, 213, 10.1097/00043798-199604000-00014 Nordestgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women, JAMA, 298, 299, 10.1001/jama.298.3.299 Langsted, 2011, Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up, J. Intern. Med., 270, 65, 10.1111/j.1365-2796.2010.02333.x Langlois, 2018, Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM, Clin. Chem., 64, 1006, 10.1373/clinchem.2018.287037 Schaefer, 2004, Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects, Am. J. Cardiol., 93, 31, 10.1016/j.amjcard.2003.09.008 Xiao, 2016, Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol, Diabetes, 65, 1767, 10.2337/db16-0046 Dobiasova, 2006, AIP–atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice, Vnitr. Lek., 52, 64 Avezum, 2017, Secondary CV Prevention in South America in a Community Setting: The PURE Study, Glob. Heart., 12, 305, 10.1016/j.gheart.2016.06.001 Halcox, 2017, Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study, BMC Cardiovasc. Disord., 17, 160, 10.1186/s12872-017-0591-5 INEGI, Instituto Nacional de Salud Pública. Secretaría de Salud. Estados Unidos Mexicanos. Encuesta Nacional de Salud y Nutrición 2018. Presentación de resultados. Available from: https://ensanut.insp.mx/encuestas/ensanut2018/doctos/informes/ensanut_2018_presentacion_resultados.pdf. (Accessed Feb 2020). Waters, 2009, Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals, Circulation, 120, 28, 10.1161/CIRCULATIONAHA.108.838466 Kim, 2013, Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1, Int. J. Cardiol., 168, 2678, 10.1016/j.ijcard.2013.03.027 Salazar, 2012, Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women, Am. J. Cardiol., 109, 1749, 10.1016/j.amjcard.2012.02.016 Cai, 2017, The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population, Medicine (Baltimore), 96, e8058, 10.1097/MD.0000000000008058